课题基金 / 基金详情

项目摘要

项目成果

MICHAEL A TAINSKY的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): When cancer is identified at the earliest stages, cancer survival rates dramatically increase and therefore diagnostic screening tests that can detect early stage cancer are crucial. The overall goal of our research is to develop such an early detection screening test. We intend to prospectively accrue a large well-defined independent cohort of colorectal cancer (CRC) cases where we collect extensive data on this cohort at the time of diagnosis. We will generate a comprehensive database that includes data on demographics, personal and family history, tumor characteristics, and comorbidities. Our preliminary research efforts have been to develop a detection assay utilizing the sera of our discovery cohort of CRC patients and healthy controls. We have developed a high throughput method to isolated cDNA clones of antigens which can be used to identify cancer cases by detecting the presence of auto-antibodies to tumor proteins in the serum of the test subject. Our first aim is to identify the minimal number of antigen clones that are critical in distinguishing sera from patients with colorectal cancer from healthy controls utilizing our initial discovery cohort. We will eliminate antigen clones from our discovery set of 3800 clones that react with sera from patients with other cancers, benign gastrointestinal conditions, duplicates or do not react with any CRC sera. Our second aim is to determine the test characteristics (sensitivity, specificity, accuracy) on these newly selected antigen markers for distinguishing colorectal cancer cases using newly acquired sera samples not previously used in the development of the marker set. Lastly, we intend to determine the test characteristics of these antigen markers on a large independent well-defined cohort of colorectal cancer patients and healthy controls. In addition, due to the size, racial/ethnic makeup of the study population, and captured patient data, we will be able to evaluate the expression of these markers in relationship to important subgroups.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of Cell-based Functional Tests for Rare Germline ATM Gene Variants in Hereditary Ovarian Cancer Families
  • 批准号:
    9307327
  • 项目类别:
  • 资助金额:
    $7.7万
  • 财政年份:
    2017
  • 负责人:
    MICHAEL A TAINSKY
  • 依托单位:
Diagnostic Assays for OVCA Recurrence using Paraneoplastic Antigens and Epitopes
  • 批准号:
    8887317
  • 项目类别:
  • 资助金额:
    $19.84万
  • 财政年份:
    2014
  • 负责人:
    MICHAEL A TAINSKY
  • 依托单位:
Diagnostic Assays for OVCA Recurrence using Paraneoplastic Antigens and Epitopes
  • 批准号:
    8753213
  • 项目类别:
  • 资助金额:
    $16.53万
  • 财政年份:
    2014
  • 负责人:
    MICHAEL A TAINSKY
  • 依托单位:
Validation of an Antibody Test for Early Diagnosis of Ovarian Cancer
  • 批准号:
    8154030
  • 项目类别:
  • 资助金额:
    $31.54万
  • 财政年份:
    2011
  • 负责人:
    MICHAEL A TAINSKY
  • 依托单位:
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2022
  • 负责人:
    王亚伟
  • 依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究